STOCK TITAN
  1. Home
  2. News
  3. MAIA

MAIA Biotechnology, Inc. - MAIA STOCK NEWS

Welcome to our dedicated page for MAIA Biotechnology news (Ticker: MAIA), a resource for investors and traders seeking the latest updates and insights on MAIA Biotechnology stock.

MAIA Biotechnology, Inc. (symbol: MAIA) is a pioneering clinical-stage biopharmaceutical company with a strong focus on targeted immunotherapies for cancer. Headquartered in Chicago, this privately-held company is driven by a dedicated management team with extensive experience in drug development. MAIA Biotechnology is committed to creating first-in-class drugs with novel mechanisms of action aimed at significantly improving and extending the lives of cancer patients.

At the core of MAIA's operations is the development of innovative therapies such as THIO, a promising cancer telomere-targeting agent currently undergoing clinical trials for the treatment of telomerase-positive cancer cells. The company's strategy is to build a diverse portfolio of potentially breakthrough compounds, each with unique mechanisms of action and potential efficacy across various tumor types. This approach not only mitigates risk but also enhances the opportunity for success in the competitive biopharmaceutical landscape.

MAIA’s unique business model involves placing drug candidates into their specialized, R&D-focused subsidiary companies. These subsidiaries are supported by a common infrastructure, making the overall operation more efficient and focused. This structure allows MAIA to concentrate on advancing its most promising agents into human clinical trials, ensuring that the most effective therapies reach patients as swiftly as possible.

In recent developments, MAIA has made significant strides in its clinical programs, securing valuable partnerships and achieving critical milestones. These advances demonstrate the company's unwavering commitment to innovation and excellence in oncology treatment. Investors and stakeholders can stay informed of MAIA’s latest news, achievements, and ongoing projects, which reflect the company's potential for future growth and impact in the field of cancer treatment.

News

MAIA Biotechnology to Present at Biotech Showcase 2024 on January 9, 2024

Rhea-AI Summary
MAIA Biotechnology, Inc. (MAIA) announced its participation in the Biotech Showcase™ 2024 investor conference in San Francisco. Chairman and CEO Vlad Vitoc, MD, MBA, will present an update on the Company’s lead program, THIO, a potential first-in-class telomere targeting agent for non-small cell lung cancer (NSCLC). Preliminary data from the ongoing THIO-101 Phase 2 trial includes an unprecedented disease control rate (DCR) of 100% in second-line NSCLC treatment. Dr. Vitoc will discuss multiple value-driving Company milestones expected in 2024 and beyond.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.89%
Tags
conferences
-
News

MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer

Rhea-AI Summary
MAIA Biotechnology, Inc. (NYSE American: MAIA) announced the selection of a dose for THIO-101, a Phase 2 clinical trial evaluating its lead asset, THIO, in combination with Regeneron’s anti-PD-1 cemiplimab in patients with advanced non-small cell lung cancer (NSCLC). The selected dose of 180mg/cycle showed better safety profile and outperformed other doses in efficacy measures, exceeding disease control rate thresholds and showing promising preliminary response rates. MAIA plans to pursue accelerated approval for THIO in the U.S. for the treatment of advanced NSCLC patients, believing in its potential to define the standard of care for this patient population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.43%
Tags
clinical trial
-
News

MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering

Rhea-AI Summary
MAIA Biotechnology, Inc. (NYSE American: MAIA) announced the closing of a registered direct offering for 2,424,243 shares of common stock at $1.65 per share, alongside a private placement of unregistered warrants for the same number of shares. H.C. Wainwright & Co. acted as the exclusive placement agent, resulting in gross proceeds of approximately $4 million for MAIA. The net proceeds will be used for working capital, general corporate purposes, and research and development activities. The offering was made under a 'shelf' registration statement on Form S-3, declared effective by the SEC. Unregistered warrants issued in the private placement may not be reoffered or resold in the United States without registration or an applicable exemption.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.57%
Tags
offering
News

MAIA Biotechnology (NYSE: MAIA) Has Received FDA Orphan Drug Designation For THIO As A Treatment For Most Aggressive Brain Cancer

Rhea-AI Summary
MAIA Biotechnology Inc. (NYSE:MAIA) has received orphan drug designation from the U.S. FDA for its cancer telomere-targeting agent, THIO, for the treatment of glioblastoma, a rare and aggressive form of brain cancer. The designation highlights the FDA's recognition of THIO's potential to treat multiple types of cancers, including rare ones like glioblastoma. With limited treatment options available for glioblastoma patients, MAIA's lead program, THIO, has the potential to improve outcomes for these patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.57%
Tags
clinical trial
-
News

MAIA Biotechnology Announces $4 Million Registered Direct Offering

Rhea-AI Summary
MAIA Biotechnology, Inc. (NYSE American: MAIA) Announces Registered Direct Offering and Private Placement
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.73%
Tags
offering
-
News

FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma

Rhea-AI Summary
MAIA Biotechnology, Inc. (NYSE American: MAIA) announced that the U.S. FDA has granted orphan drug designation to its lead asset THIO for the treatment of glioblastoma. This is the third ODD granted to THIO, highlighting its potential in treating multiple cancer indications. Expected market growth from $2.2 billion to $3.2 billion globally in the next three years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.86%
Tags
clinical trial
News

MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO

Rhea-AI Summary
MAIA Biotechnology, Inc. reported a 100% disease control rate in second-line non-small cell lung cancer with their lead asset THIO, along with positive findings in gliomas, pediatric brain cancer, and second-generation THIO-derived cancer therapies. The company also achieved FDA clearance for THIO studies in the U.S. and is experiencing a strong pace of enrollment in their THIO-101 Phase 2 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
earnings
-
News

MAIA Biotechnology Reports Positive Phase 2 Clinical Trial Data On Its Treatment For Non-Small Cell Lung Cancer

Rhea-AI Summary
MAIA Biotechnology reports positive phase 2 clinical trial data on its treatment for non-small cell lung cancer, showing a 100% Disease Control Rate (DCR) in second-line treatment and an 88% DCR in third-line treatment, surpassing standard-of-care rates. The trial is ahead of schedule and aims to evaluate the efficacy of THIO followed by PD-(L)1 inhibition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.5%
Tags
clinical trial
-
News

MAIA Biotechnology Reveals Higher Anticancer Potency of Telomere-Targeting Compounds Derived from THIO

Rhea-AI Summary
MAIA Biotechnology announces positive results from an investigational new drug-enabling study of its second-generation telomere-targeting agents derived from lipid-modified THIO molecules. The study demonstrated broad-spectrum therapeutically-attractive opportunities for specific telomeric stress-inducing treatments. Initial in vivo evaluation showed potent anticancer activity at relatively low dose levels for one of the lead lipid conjugates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.82%
Tags
none
News

MAIA Biotechnology Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial

Rhea-AI Summary
MAIA Biotechnology reports positive preliminary efficacy data from Phase 2 clinical trial for NSCLC treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.1%
Tags
clinical trial

FAQ

What is the current stock price of MAIA Biotechnology (MAIA)?

The current stock price of MAIA Biotechnology (MAIA) is $3.32 as of November 7, 2024.

What is the market cap of MAIA Biotechnology (MAIA)?

The market cap of MAIA Biotechnology (MAIA) is approximately 82.0M.

What does MAIA Biotechnology, Inc. specialize in?

MAIA Biotechnology specializes in developing first-in-class drugs with novel mechanisms of action, primarily focused on targeted immunotherapies for cancer.

What is MAIA Biotechnology's core drug development program?

MAIA's core program is THIO, a potential cancer telomere-targeting agent in clinical development for treating telomerase-positive cancer cells.

Where is MAIA Biotechnology headquartered?

MAIA Biotechnology is headquartered in Chicago.

What is MAIA's business model?

MAIA's business model involves placing drug candidates into dedicated, R&D-focused subsidiary companies, which are supported by a common infrastructure.

How does MAIA Biotechnology manage risk in its drug development process?

MAIA manages risk by diversifying its portfolio with various compounds that have novel mechanisms of action and potential effectiveness across multiple tumor types.

Who leads MAIA Biotechnology?

MAIA is led by a passionate and experienced management team with significant expertise in drug development.

What recent achievements has MAIA Biotechnology made?

MAIA has made significant strides in its clinical programs, securing valuable partnerships and achieving critical milestones in cancer treatment development.

Is MAIA Biotechnology a public or private company?

MAIA Biotechnology is a privately-held company.

How can I stay updated with the latest news about MAIA Biotechnology?

You can stay updated with the latest news by following MAIA Biotechnology on stock market websites like StockTitan and other financial news platforms.

Stock MAIA logo
MAIA Biotechnology, Inc.

NYSE:MAIA

MAIA Rankings

#4534 Ranked by Market Cap
N/A Ranked by Dividends

MAIA Stock Data

81.97M
23.91M
16.32%
7.43%
2.91%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CHICAGO